European Commission Authorizes Daraxonrasib in Pancreatic Cancer

Company Revolution Medicines Event Type European Commission marketing authorization (previously missed 16 Nov event) Modality Oral RAS(ON) multi-selective inhibitor Asset Rasonque (daraxonrasib) Target RAS(ON) Disease Area Metastatic pancreatic adenocarcinoma Summary The European Commission granted marketing authorization on November 16 for Rasonque, daraxonrasib, as monotherapy in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *